Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT

Core Viewpoint - Altimmune, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between August 10, 2023, and June 25, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit was initiated following Altimmune's announcement on June 26, 2025, regarding the topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [2]. - The company's prior communications had created inflated expectations, but the trial results revealed a higher-than-expected placebo response, leading to a significant stock price drop [2]. - Following the announcement, Altimmune's stock plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, highlighting its expertise in complex securities litigation [4].